Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors "A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome"
- PMID: 27194054
- PMCID: PMC11029564
- DOI: 10.1007/s00262-016-1845-2
Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors "A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome"
Conflict of interest statement
James Larkin is a non-remunerated consultant for Novartis, Pfizer, BMS, MSD and Roche/Genentech and receives institutional research support from Pfizer, BMS, Novartis, and MSD. Lavinia Spain and Juan Martin-Liberal have no relevant disclosures.
Comment on
-
A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome.Cancer Immunol Immunother. 2016 Jun;65(6):765-7. doi: 10.1007/s00262-016-1835-4. Epub 2016 Apr 11. Cancer Immunol Immunother. 2016. PMID: 27067877 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
